Recombinant Human VSIG2 Fc Chimera Protein, CF

2 μg/lane of Recombinant Human VSIG2 was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® blue staining, showing bands at 54-65 kDa and 100-130 kDa, respectively.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human VSIG2 Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its ability to inhibit anti-CD3 antibody induced IFN-gamma secretion by human peripheral blood mononuclear cells (PBMC). The ED 50 for this effect is 5-25 μg/mL.
• Source: Mouse myeloma cell line, NS0-derived human VSIG2 protein

  Human VSIG2 (Val24-Ala243) Accession # Q96IQ7-1

  IEGRMD

  Human IgG 1 (Pro100-Lys330)

  N-terminus

  C-terminus

• Accession #: Q96IQ7-1
• N-terminal Sequence: Val24
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 50 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 54-65 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage:
  12 months from date of receipt, ≤ -20 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 3 months, ≤ -20 degreesC under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human VSIG2 Fc Chimera Protein, CF

• 2210413P10Rik
• Cortical thymocyte-like protein
• CTH
• CTHCTXLcortical thymocyte receptor (X. laevis CTX) like
• CT-like protein
• CTXL
• V-set and immunoglobulin domain containing 2
• V-set and immunoglobulin domain-containing protein 2
• VSIG2

Background

V-set and immunoglobulin domain-containing protein 2 (VSIG2), also known as cortical thymocyte-like protein (CT-like protein), is a member of the immunoglobulin superfamily (Igsf) that was originally described in Xenopus and was referred to as cortical thymocyte marker in Xenopus, or CTX. The clone isolated from the human genomic library was called CTH (1). Mature human VSIG2 is a single-pass type I transmembrane protein with a 220 amino acid (aa) extracellular domain (ECD) that contains one C2-type and one V-type immunoglobulin-like domains, and a 63 aa cytoplasmic region linked to the ECD by a short 21 aa transmembrane domain. Human VSIG2 ECD shares 85% and 86% aa sequence identity with mouse and rat VSIG2, respectively. VSIG2 is structurally related to the B7 family of immune regulatory proteins. Our studies at R&D Systems show that VSIG2 inhibits T cell activation, including IL17 and interferon gamma production.

1. Chrétien, I. et al. (1998) Eur. J. Immunol. 28:4094.

Bioinformatics

• Uniprot:
  • Q96IQ7-1()